In this edition of our Inside Global Pharma podcast series, Jennifer Curtis connects with Josh Hattem to discuss trends in oncology portfolio strategy, building on a previous episode, “The value of focus.”
Highlights from the episode:
- The oncology therapy area’s future is not as certain as it was in the past; blockbuster launches sold 47% higher on average in 2012-2016 compared to 2017-2021
- A range of factors contributed to this drop, including intense competition, smaller, more fragmented opportunities and the entrance of emerging pharma players into the space
- The latest ZS research suggests intentional use of the customer lens early in portfolio strategy development could help companies “win” in oncology by enhancing “share of mind”
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
